Analyst rating shifts in energy and biotech sectors

Market analysts have issued various rating adjustments and price target shifts across the energy and biotechnology sectors.

In the energy sector, Fluence Energy has faced significant downward pressure. Following a downgrade from Zacks Research from a ‘strong-buy’ to a ‘hold’ rating and a price target reduction from Citigroup, Barclays lowered its rating from ‘equal weight’ to ‘underweight’, reducing its price target from $16.00 to $10.00. Glj Research also downgraded the stock to a ‘hold’ rating. Consequently, Fluence Energy shares experienced a 6.5% decline during mid-day trading, reaching a low of $10.38.

Conversely, Bloom Energy continues to see increased demand for hydrogen fuel cells driven by the expansion of artificial intelligence infrastructure, which necessitates off-grid power solutions. While its product backlog has grown, much of its value remains tied to long-term service contracts.

Within the biotechnology and life sciences sectors, Moderna received an upgrade from Argus from ‘hold’ to ‘buy’ with a $180.00 price target, although the broader market maintains an average ‘hold’ rating. Maravai LifeSciences was downgraded to a ‘hold’ rating by Wall Street Zen. Other firms maintained positive outlooks: Mirum Pharmaceuticals saw its ‘market outperform’ rating reiterated by Citizens Jmp with a $137.00 target price, and Roivant Sciences received a reiterated ‘buy’ rating and $41.00 target price from HC Wainwright, contributing to a consensus ‘moderate buy’ rating.